A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

Summary

The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated. This study will last approximately 3 weeks for each participant, including check-in and follow-up.

Timeline

Start

2015-03

Primary completion

2015-08

Completion

2015-08

Drugs

Indications